Intrathecal pemetrexed

DRUG4 trials

Sponsors

Hunan Province Tumor Hospital, Fujian Cancer Hospital, Shuanghu Yuan

Conditions

Leptomeningeal MetastasisLeptomeningeal Metastasis From Lung CancerNon-Small Cell Lung CancerSmall-cell Lung Cancer

Phase 2

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

RecruitingNCT06440954

Hunan Province Tumor HospitalNon-Small Cell Lung Cancer

Start: 2024-05-01End: 2027-04-30Target: 220Updated: 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Not yet recruitingNCT06441045

Fujian Cancer HospitalLeptomeningeal Metastasis

Start: 2024-10-01End: 2028-10-01Target: 112Updated: 2024-06-04

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Not yet recruitingNCT06497543

Hunan Province Tumor HospitalSmall-cell Lung Cancer

Start: 2024-10-01End: 2026-04-30Target: 80Updated: 2024-09-19

Unknown Phase

ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

RecruitingNCT07751536

Shuanghu YuanLeptomeningeal Metastasis From Lung Cancer

Start: 2026-08-05End: 2028-07-31Target: 84Updated: 2026-08-07